Related Experiment Video

Updated: May 28, 2026

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway

Wenrong Gong1, Qibin Song, Xiaoming Lu

  • 1Department of Clinical Laboratory, the Affiliated Hospital of XiangFan University, XiangFan 441021, Hubei, China.

Journal of Chemotherapy (Florence, Italy)
|October 19, 2011
PubMed

Insights

Paclitaxel (PTX) increases B7-H1 immunosuppressive molecule expression in cancer cells through transcriptional and post-transcriptional pathways, potentially contributing to tumor immune evasion.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Paclitaxel (PTX) is a chemotherapy agent.
  • B7-H1 is an immunosuppressive molecule involved in tumor immune evasion.
  • Understanding PTX's effects on B7-H1 is crucial for cancer therapy.

Purpose of the Study:

  • To investigate the mechanisms of PTX-induced B7-H1 expression in colorectal and hepatocellular carcinoma cells.
  • To elucidate the role of the Erk1/2 pathway in PTX-mediated B7-H1 upregulation.

Main Methods:

  • Utilized immunofluorescence and flow cytometry to assess B7-H1 protein levels.
  • Employed real-time quantitative PCR for mRNA expression analysis.
  • Investigated the effect of MEK inhibitor U0126 on PTX-induced B7-H1 expression.

Main Results:

  • PTX significantly increased B7-H1 protein and mRNA expression in SW480 and HepG2 cells.
  • PTX treatment induced Erk1/2 phosphorylation in both cell lines.
  • MEK inhibitor U0126 partially blocked PTX-induced B7-H1 protein expression but significantly inhibited mRNA upregulation.

Conclusions:

  • PTX upregulates B7-H1 expression via both transcriptional and post-transcriptional mechanisms.
  • The Erk1/2 pathway plays a role in PTX-induced B7-H1 mRNA expression.
  • Findings may enhance understanding of PTX-related tumor immune evasion strategies.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...